CENPE Inhibition Leads to Mitotic Catastrophe and DNA Damage in Medulloblastoma Cells
- PMID: 33804489
- PMCID: PMC7957796
- DOI: 10.3390/cancers13051028
CENPE Inhibition Leads to Mitotic Catastrophe and DNA Damage in Medulloblastoma Cells
Abstract
Medulloblastoma (MB) is the most frequent brain tumor in children. The standard treatment consists in surgery, followed by radiotherapy and chemotherapy. These therapies are only partially effective since many patients still die and those who survive suffer from neurological and endocrine disorders. Therefore, more effective therapies are needed. Primary microcephaly (MCPH) is a rare disorder caused by mutations in 25 different genes. Centromere-associated protein E (CENPE) heterozygous mutations cause the MCPH13 syndrome. As for other MCPH genes, CENPE is required for normal proliferation and survival of neural progenitors. Since there is evidence that MB shares many molecular features with neural progenitors, we hypothesized that CENPE could be an effective target for MB treatment. In ONS-76 and DAOY cells, CENPE knockdown induced mitotic defects and apoptosis. Moreover, CENPE depletion induced endogenous DNA damage accumulation, activating TP53 or TP73 as well as cell death signaling pathways. To consolidate CENPE as a target for MB treatment, we tested GSK923295, an allosteric inhibitor already in clinical trial for other cancer types. GSK923295, induced effects similar to CENPE depletion with higher penetrance, at low nM levels, suggesting that CENPE's inhibition could be a therapeutic strategy for MB treatment.
Keywords: 53BP1; CENPE; DNA damage; childhood brain tumor; microcephaly; mitotic catastrophe; γH2AX.
Conflict of interest statement
The authors declare no conflict of interest.
Figures











Similar articles
-
Primary microcephaly gene CENPE is a novel biomarker and potential therapeutic target for non-WNT/non-SHH medulloblastoma.Front Immunol. 2023 Aug 1;14:1227143. doi: 10.3389/fimmu.2023.1227143. eCollection 2023. Front Immunol. 2023. PMID: 37593739 Free PMC article.
-
Inhibiting microcephaly genes as alternative to microtubule targeting agents to treat brain tumors.Cell Death Dis. 2021 Oct 18;12(11):956. doi: 10.1038/s41419-021-04259-6. Cell Death Dis. 2021. PMID: 34663805 Free PMC article. Review.
-
XAB2 functions in mitotic cell cycle progression via transcriptional regulation of CENPE.Cell Death Dis. 2016 Oct 13;7(10):e2409. doi: 10.1038/cddis.2016.313. Cell Death Dis. 2016. PMID: 27735937 Free PMC article.
-
Inactivation of Citron Kinase Inhibits Medulloblastoma Progression by Inducing Apoptosis and Cell Senescence.Cancer Res. 2018 Aug 15;78(16):4599-4612. doi: 10.1158/0008-5472.CAN-17-4060. Epub 2018 Jun 19. Cancer Res. 2018. PMID: 29921697
-
Comprehensive review on the molecular genetics of autosomal recessive primary microcephaly (MCPH).Genet Res (Camb). 2018 Aug 8;100:e7. doi: 10.1017/S0016672318000046. Genet Res (Camb). 2018. PMID: 30086807 Free PMC article. Review.
Cited by
-
The impact of TP53 activation and apoptosis in primary hereditary microcephaly.Front Neurosci. 2023 Jun 28;17:1220010. doi: 10.3389/fnins.2023.1220010. eCollection 2023. Front Neurosci. 2023. PMID: 37457016 Free PMC article. Review.
-
Kinesin-7 CENP-E mediates chromosome alignment and spindle assembly checkpoint in meiosis I.Chromosoma. 2024 Apr;133(2):149-168. doi: 10.1007/s00412-024-00818-w. Epub 2024 Mar 8. Chromosoma. 2024. PMID: 38456964
-
CENPE is a diagnostic and prognostic biomarker for cervical cancer.Heliyon. 2024 Dec 4;10(24):e40860. doi: 10.1016/j.heliyon.2024.e40860. eCollection 2024 Dec 30. Heliyon. 2024. PMID: 39759304 Free PMC article.
-
Lin28A/CENPE Promoting the Proliferation and Chemoresistance of Acute Myeloid Leukemia.Front Oncol. 2021 Nov 12;11:763232. doi: 10.3389/fonc.2021.763232. eCollection 2021. Front Oncol. 2021. PMID: 34868981 Free PMC article.
-
Lestaurtinib inhibits Citron kinase activity and medulloblastoma growth through induction of DNA damage, apoptosis and cytokinesis failure.Front Oncol. 2023 Jun 19;13:1202585. doi: 10.3389/fonc.2023.1202585. eCollection 2023. Front Oncol. 2023. PMID: 37404750 Free PMC article.
References
-
- Triscott J., Lee C., Foster C., Manoranjan B., Pambid M.R., Berns R., Fotovati A., Venugopal C., O’Halloran K., Narendran A., et al. Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children. Cancer Res. 2013;73:6734–6744. doi: 10.1158/0008-5472.CAN-12-4331. - DOI - PubMed
-
- Cho Y.-J., Tsherniak A., Tamayo P., Santagata S., Ligon A., Greulich H., Berhoukim R., Amani V., Goumnerova L., Eberhart C.G., et al. Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. J. Clin. Oncol. 2011;29:1424–1430. doi: 10.1200/JCO.2010.28.5148. - DOI - PMC - PubMed
-
- Kool M., Korshunov A., Remke M., Jones D.T.W., Schlanstein M., Northcott P.A., Cho Y.-J., Koster J., Schouten-van Meeteren A., van Vuurden D., et al. Molecular Subgroups of Medulloblastoma: An International Meta-Analysis of Transcriptome, Genetic Aberrations, and Clinical Data of WNT, SHH, Group 3, and Group 4 Medulloblastomas. Acta Neuropathol. 2012;123:473–484. doi: 10.1007/s00401-012-0958-8. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous